Pliant Therapeutics reprices COO stock options

Pliant Therapeutics, Inc. Chief Operating Officer Minnie Kuo reported an option repricing affecting her existing stock options.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Pliant Therapeutics, Inc. Chief Operating Officer Minnie Kuo reported an option repricing affecting her existing stock options. On the April 17, 2026 effective date, she surrendered options covering 150,000, 40,000 and 55,200 shares of common stock with exercise prices of $16.18, $17.44 and $11.14, respectively, and received new options for the same share amounts at an exercise price of $1.33 per share.

The board approved this company‑wide repricing on April 15, 2026 for options granted on or before March 1, 2025, and all other terms, including vesting under the 2020 and 2022 plans, remain unchanged. The repriced awards may revert to their original exercise prices if exercised during an eighteen‑month “Retention Period” starting on the effective date, or if Kuo is terminated for cause or resigns (other than for good reason) before that period ends, subject to the detailed conditions described.

Insider Trade Summary

6 transactions reported

Mixed 6 txns

Insider Kuo Minnie

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Disposition	Stock Option (Right to Buy)	150,000	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	150,000	$0.00	$0.00
Disposition	Stock Option (Right to Buy)	40,000	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	40,000	$0.00	$0.00
Disposition	Stock Option (Right to Buy)	55,200	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	55,200	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 245,200 contracts (Direct)

Footnotes (4)

F1. On April 15, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged.
F2. The stock option award was issued pursuant to the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan") or the Issuer's 2022 Inducement Plan, as amended (the "2022 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's Form 3, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date.
F3. The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Sales Event (as defined by the 2020 Plan or the 2022 Plan, as applicable); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan).
F4. The repriced options will also revert to its original exercise price if the Reporting Period (i) is terminated for cause (as defined in the Reporting Person's severance plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan).

Key Figures

Repriced options block 1: 150,000 shares at $1.33 Repriced options block 2: 40,000 shares at $1.33 Repriced options block 3: 55,200 shares at $1.33 +2 more

5 metrics

Repriced options block 1 150,000 shares at $1.33 Replaces prior $16.18 options, expires on 2033-09-14

Repriced options block 2 40,000 shares at $1.33 Replaces prior $17.44 options, expires on 2034-01-23

Repriced options block 3 55,200 shares at $1.33 Replaces prior $11.14 options, expires on 2035-01-23

Retention Period length 18 months From April 17, 2026 effective date of repricing

Repricing approval date April 15, 2026 Board approved option repricing for eligible employees

Key Terms

option repricing, Retention Period, Sales Event, 2020 Stock Option and Incentive Plan, +1 more

5 terms

option repricing financial

"the Issuer's board of directors approved an option repricing (the "Repricing")"

Retention Period financial

"The "Retention Period" commenced on the Effective Date and ends on the earliest of the following"

Sales Event financial

"the consummation of a Sales Event (as defined by the 2020 Plan or the 2022 Plan, as applicable)"

2020 Stock Option and Incentive Plan financial

"issued pursuant to the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan")"

2022 Inducement Plan financial

"or the Issuer's 2022 Inducement Plan, as amended (the "2022 Plan"), as applicable"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Minnie Kuo’s Form 4 for PLIANT THERAPEUTICS (PLRX) report?

The Form 4 reports an option repricing for Chief Operating Officer Minnie Kuo. She surrendered several existing stock options and received new options over the same share amounts at a lower exercise price of $1.33 per share, with all other terms unchanged.

How many PLRX stock options were repriced for COO Minnie Kuo?

The filing shows repricing of options over 150,000, 40,000 and 55,200 shares of Pliant common stock. Each original grant was disposed of and replaced one‑for‑one, keeping the total underlying share counts the same while changing only the exercise prices.

What new exercise price applies to Minnie Kuo’s repriced PLRX options?

Each repriced stock option now has an exercise price of $1.33 per share. The filing notes this reflects the closing price of Pliant’s common stock on the April 17, 2026 effective date, while vesting schedules and other option terms remain the same.

What is the Retention Period in the PLRX option repricing for Minnie Kuo?

The Retention Period starts on the April 17, 2026 effective date and ends on the earliest of eighteen months later, a qualifying Sales Event, or specified termination events. Exercising repriced options during this Retention Period causes them to revert to their original exercise prices.

Under what conditions do Minnie Kuo’s repriced PLRX options revert to original prices?

The repriced options revert to their original exercise prices if exercised during the Retention Period. They also revert if Kuo is terminated for cause or resigns before the Retention Period ends, except when resignation is for good reason as defined in her severance plan.

Do Minnie Kuo’s repriced PLRX options change vesting or plan terms?

The filing states that all other option terms remain unchanged. The repriced awards continue to vest under the original schedules specified in agreements issued under Pliant’s 2020 Stock Option and Incentive Plan or 2022 Inducement Plan, subject to continued service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 04/17/2026 - 04:42 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kuo Minnie

(Last)

(First)

(Middle)

C/O PLIANT THERAPEUTICS, INC.

331 OYSTER POINT BOULEVARD

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PLIANT THERAPEUTICS, INC. [ PLRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$16.18	04/17/2026		D⁽¹⁾			150,000	⁽²⁾	09/14/2033	Common Stock	150,000	$0	0	D
Stock Option (Right to Buy)	$1.33⁽³⁾⁽⁴⁾	04/17/2026		A⁽¹⁾		150,000		⁽²⁾	09/14/2033	Common Stock	150,000	$0	150,000	D
Stock Option (Right to Buy)	$17.44	04/17/2026		D⁽¹⁾			40,000	⁽²⁾	01/23/2034	Common Stock	40,000	$0	0	D
Stock Option (Right to Buy)	$1.33⁽³⁾⁽⁴⁾	04/17/2026		A⁽¹⁾		40,000		⁽²⁾	01/23/2034	Common Stock	40,000	$0	40,000	D
Stock Option (Right to Buy)	$11.14	04/17/2026		D⁽¹⁾			55,200	⁽²⁾	01/23/2035	Common Stock	55,200	$0	0	D
Stock Option (Right to Buy)	$1.33⁽³⁾⁽⁴⁾	04/17/2026		A⁽¹⁾		55,200		⁽²⁾	01/23/2035	Common Stock	55,200	$0	55,200	D

Explanation of Responses:

1. On April 15, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged.

2. The stock option award was issued pursuant to the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan") or the Issuer's 2022 Inducement Plan, as amended (the "2022 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's Form 3, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting date.

3. The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Sales Event (as defined by the 2020 Plan or the 2022 Plan, as applicable); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan).

4. The repriced options will also revert to its original exercise price if the Reporting Period (i) is terminated for cause (as defined in the Reporting Person's severance plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan).

Remarks:

	/s/ Jennifer Woo, attorney-in-fact	04/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR